-
Signature
-
Jack W. Callicutt
-
Issuer symbol
-
GALT
-
Transactions as of
-
17 Nov 2025
-
Net transactions value
-
-$359,292
-
Form type
-
4
-
Filing time
-
19 Nov 2025, 16:01:12 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| CALLICUTT JACK W |
Chief Financial Officer |
C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS |
Jack W. Callicutt |
19 Nov 2025 |
0001266773 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
GALT |
Common stock |
Options Exercise |
$18,980 |
+9,586 |
+126% |
$1.98 |
17,200 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
GALT |
Common stock |
Sale |
$57,820 |
-9,586 |
-56% |
$6.03 |
7,614 |
17 Nov 2025 |
Direct |
F1, F5 |
| transaction |
GALT |
Common stock |
Options Exercise |
$21,868 |
+19,701 |
+259% |
$1.11 |
27,315 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
GALT |
Common stock |
Sale |
$118,831 |
-19,701 |
-72% |
$6.03 |
7,614 |
17 Nov 2025 |
Direct |
F1, F5 |
| transaction |
GALT |
Common stock |
Options Exercise |
$2,857 |
+2,323 |
+31% |
$1.23 |
9,937 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
GALT |
Common stock |
Sale |
$14,012 |
-2,323 |
-23% |
$6.03 |
7,614 |
17 Nov 2025 |
Direct |
F1, F5 |
| transaction |
GALT |
Common stock |
Options Exercise |
$55,638 |
+28,100 |
+369% |
$1.98 |
35,714 |
18 Nov 2025 |
Direct |
F1 |
| transaction |
GALT |
Common stock |
Sale |
$174,866 |
-28,100 |
-79% |
$6.22 |
7,614 |
18 Nov 2025 |
Direct |
F1, F6 |
| transaction |
GALT |
Common stock |
Options Exercise |
$20,213 |
+18,210 |
+239% |
$1.11 |
25,824 |
18 Nov 2025 |
Direct |
F1 |
| transaction |
GALT |
Common stock |
Sale |
$113,321 |
-18,210 |
-71% |
$6.22 |
7,614 |
18 Nov 2025 |
Direct |
F1, F6 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
GALT |
Stock option (right to buy) |
Options Exercise |
$0 |
-9,586 |
-25% |
$0.000000 |
28,120 |
17 Nov 2025 |
Common stock |
9,586 |
$1.98 |
Direct |
F1, F2 |
| transaction |
GALT |
Stock option (right to buy) |
Options Exercise |
$0 |
-19,701 |
-52% |
$0.000000 |
18,190 |
17 Nov 2025 |
Common stock |
19,701 |
$1.11 |
Direct |
F1, F3 |
| transaction |
GALT |
Stock option (right to buy) |
Options Exercise |
$0 |
-2,323 |
-4.5% |
$0.000000 |
48,750 |
17 Nov 2025 |
Common stock |
2,323 |
$1.23 |
Direct |
F1, F4 |
| transaction |
GALT |
Stock option (right to buy) |
Options Exercise |
$0 |
-28,120 |
-100% |
$0.000000 |
0 |
18 Nov 2025 |
Common stock |
28,120 |
$1.98 |
Direct |
F1, F2 |
| transaction |
GALT |
Common stock (right to buy) |
Options Exercise |
$0 |
-18,190 |
-100% |
$0.000000 |
0 |
18 Nov 2025 |
Common stock |
18,190 |
$1.11 |
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: